Working… Menu
Trial record 2 of 519 for:    melanoma phase III

A Phase Ⅲ Study to Investigate JS001 Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03430297
Recruitment Status : Recruiting
First Posted : February 12, 2018
Last Update Posted : May 10, 2018
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : December 2019